Home / Politics / Policy /  SC issues notice to Ranbaxy, Centre for adulterated drugs

The Supreme Court on Friday issued a notice to Ranbaxy Laboratories Ltd and the Centre after hearing a public interest litigation seeking a probe against the drug maker for allegedly supplying adulterated and ineffective drugs in the country.

The petitioner, Manohar Lal Sharma, referred to a recent order by the US Food and Drug Administration (FDA) directing Ranbaxy to withdraw its generic version of Pfizer Inc.’s cholesterol lowering medicine Lipitor from the US due to dosage mix-ups.

In his interim application, Sharma urged the Supreme Court to order the seizure of all stock of Ranbaxy’s cholesterol medication available for supply to the market and to prohibit it from manufacturing the drug or any products banned in the US by the FDA till further orders.

Sharma called for probes by the Central Bureau of Investigation (CBI) and an independent special investigating team.

Sharma, an advocate, last year filed a public interest litigation for the prosecution of Ranbaxy directors and the cancellation of the company’s manufacturing licence.

In 2012, Ranbaxy Laboratories reached reached a $500 million settlement with the FDA for allegedly falsifying data and selling substandard drugs. T

hough probes have been conducted on Ranbaxy’s manufacturing facilities in Mohali and Paonta Sahib, the Drug Standards Control Organization had not found any major discrepancies.

Catch all the Politics News and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Recommended For You

Trending Stocks

Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout